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Block copolymers composed of poly(3-hydroxyoctanoate) (PHO) and methoxy poly(ethylene glycol) (PEG) were
synthesized to prepare paclitaxel-incorporated nanoparticle for antitumor drug delivery. In a 1H-NMR study, chemical
structures of PHO/PEG block copolymers were confirmed and their molecular weight (M.W.) was analyzed with gel
permeation chromatography (GPC). Paclitaxel as a model anticancer drug was incorporated into the nanoparticles of
PHO/PEG block copolymer. They have spherical shapes and their particle sizes were less than 100 nm. In a 1H-NMR
study in D2O, specific peaks of PEG solely appeared while peaks of PHO disappeared, indicating that nanoparticles have
core-shell structures. The higher M.W. of PEG decreased loading efficiency and particle size. The higher drug feeding
increased drug contents and average size of nanoparticles. In the drug release study, the higher M.W. of PEG block
induced the acceleration of drug release rate. The increase in drug contents induced the slow release rate of drug. In
an antitumor activity study in vitro, paclitaxel nanoparticles have practically similar anti-proliferation activity against
HCT116 human colon carcinoma cells. In an in vivo animal study using HCT116 colon carcinoma cell-bearing mice,
paclitaxel nanoparticles have enhanced antitumor activity compared to paclitaxel itself. Therefore, paclitaxel-incorporated
nanoparticles of PHO/PEG block copolymer are a promising vehicle for antitumor drug delivery.
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Nanoparticles have been extensively investigated in the
biomedical field as a drug delivery vehicle due to their
properties such as small particle size less than 1,000 nm,
favorable biodistribution, and drug targeting possibility
[1,2]. Among them, core-shell type nanoparticles have
great potentials in the antitumor drug delivery system
since they have intrinsic properties, i.e., hydrophobic
core as a drug reservoir and hydrophilic outershell as a
protective layer [2,3]. They have superior properties such
as extended blood circulation time of drug, passive tar-
geting of solid tumor, dissolution of hydrophobic drugs,
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in any medium, provided the original work is pPoly(3-hydroxyoctanoate) (PHO) is one of the polyesters
derived from bacterial source [4,5]. PHO has attractive
properties as a biomedical material such as low melting
temperature and crystallinity and excellent elastomeric
and mechanical properties compared to other kinds of
polyhydroxyalkanoates [4-6]. The drawback of PHO is
slower degradation rate and higher hydrophobic proper-
ties than other kinds of PHAs [6]. Therefore, various
chemical modifications of PHO have been attempted to
endow hydrophilic properties and to improve mechanical
properties as a biomedical material [5,7].
In this study, we synthesized block copolymers com-
posed of PHO/PEG to make core-shell-typed nanoparti-
cles and to fabricate suitable vehicles for antitumor drug
delivery. Since PHO has hydrophobicity, it could be con-
sisted in the core of the nanoparticles while PEG must
be hydrated to the direction of aqueous environment.
Paclitaxel was selected as an anticancer agent due to its
poor aqueous solubility. Characteristics of nanoparticlesOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tumor activity of drug-incorporated nanoparticles was
studied in vitro/in vivo.
Methods
Materials
PHO was produced by Pseudomonas oleovorans ATCC
29347 (American Type Culture Collection (ATCC),
Manassas, VA 20110, USA) as reported previously [4]
and purified from the lyophilized cells by extraction
with hot chloroform [8]. The purified PHO analyzed by gas
chromatography was consisted of 7% 3-hydroxyhexanoate
and 93% 3-hydroxyoctanoate. Methoxy poly(ethylene
glycol)-amine (molecular weight (M.W.) = 2,000, 5,000,
12,000 g/mol) was purchased from Sunbio Co. Ltd.,
Cheonan, Korea. Fluorescein isothiocyanate (FITC), N,
N′-dicyclohexyl carbodiimide (DCC), and N-hydroxy-
succinimide (NHS) were purchased from Aldrich Chemical
Company (St Louis, MO, USA). The dialysis membranesFigure 1 Synthesis scheme (A) and 1H-NMR spectra of copolymers (B,
of PHO (B) and PHO/PEG 12 K (C) in CDCl3.with molecular weight cut-offs (MWCOs) of 12,000 and
8000 g/mol were purchased from Spectra/PorTM dialysis
membrane (Spectrum Laboratories Inc, Rancho Domin-
guez, CA, USA). Dichloromethane (DCM), dimethylfor-
mamide (DMF), tetrahydrofuran (THF), methanol, and
acetone were of extra pure grade.
Synthesis of PHO/PEG block copolymers
Five hundred grams of PHO were dissolved in 20 ml of
THF. Ten milligrams of DCC and 5.5 mg of NHS was
added to this solution and magnetically stirred for 6 h.
After that, the solution was filtered using filter paper to
remove by-products and the solvent was evaporated
using rotary evaporator following precipitation into
methanol. Precipitates were harvested and dried under
reduced pressure for 2 days to obtain NHS-activated
PHO as shown in Figure 1. Five hundred milligrams of
NHS-activated PHO was dissolved in 20 ml of THF and
2 equivalents of MPEG amine were added. This solutionC). Synthesis scheme of PHO/PEG block copolmyers (A). 1H-NMR spectra
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amount of methanol three times. Precipitates were har-
vested and dried under vacuum for 3 days.
Characterization of PHO/PEG block copolymer
Characterization of the synthesized polymers was per-
formed in CDCl3 by 500 mHz
1H-NMR spectroscopy
(500 mHz superconducting FT-NMR spectrometer, Var-
ian Unity Inova 500 MHz NB High Resolution FT NMR;
Varian Inc, Santa Clara, CA, USA). Molecular weight of
polymers was measured with the gel permeation chro-
matography (GPC) system (Waters 2690D-2410, Waters,
MA, USA) as described previously [5]. GPC was equipped
with a Waters 6000 solvent delivery system, RI detector,
and a Rheodyne injector. Phenogel columns of 500, 103,
104, and 105 Å were used. A standard curve was estab-
lished with standard polystyrene samples.
Preparation of paclitaxel-incorporated nanoparticles using
PHO/PEG block copoylmer
PHO/PEG block copolymer was dissolved in 5 ml of
THF and then paclitaxel dissolved in 2 ml of DMF was
added. This solution was slowly dropped into 10 ml of
cold deionized water for 15 min and then stirred mag-
netically for 60 min at 4°C. After that, this solution was
dialyzed using a dialysis tube (MWCO= 12,000 g/mol)
against deionized water for 1 day. To remove solvent,
deionized water was exchanged at every 2-h intervals.
After that, dialyzed solution was used for analysis or
lyophilization. Empty nanoparticles were prepared in the
absence of paclitaxel.
Drug content and loading efficiency were measured
using a UV-1201 spectrophotometer (Shimadzu Co. Ltd.,
Kyoto, Japan) at 273 nm. Empty nanoparticles were used
as a blank.
Morphology of the polymeric micelles was observed
using a transmission electron microscope (TEM, JEOL
JEM-2000 FX II, JEOL, Akishima-shi, Japan). One drop
of nanoparticle solution containing phosphotungstic acid
0.05% (w/w) was placed onto a carbon film coated on a
copper grid for TEM. Observation was done at 80 kV.
The particle size of the nanoparticles was measured withTable 1 Characterization of PHO/PEG block copolymers
M.W. of PEG (g/mol)a M.W. b
Mw
PHO - 57,800
PHO/PEG 2 K 2,000 60,200
PHO/PEG 5 K 5,000 63,100
PHO/PEG 12 K 12,000 70,500
aM.W. of PEG was from the manufacturer's data; bPDI (polydispersity index) was Mwdynamic laser scattering (DLS-7000, Otsuka Electronics
Company, Osaka, Japan).Drug release study
The release experiment was carried out in vitro as fol-
lows: Paclitaxel-incorporated nanoparticle solution was
prepared as described above. After the dialysis proced-
ure, the volume of nanoparticle solution was adjusted to
50 ml and then 5 ml of this solution was introduced into
a dialysis tube (MWCO= 12,000 g/mol) and then dialy-
sis tube was introduced into a 200-ml bottle with 95 ml
of phosphate-buffered saline (PBS, 0.1 M, pH 7.4, 0.1%
(w/v) Tween 80). This bottle was placed in a shaking in-
cubator with stirring speed of 100 rpm at 37°C. At spe-
cific time intervals, the media were taken for analysis of
drug concentration. After that, the whole media was re-
placed with fresh PBS to prevent drug saturation. The
concentration of the paclitaxel released into PBS was eval-
uated using a high-performance liquid chromatography
(HPLC, PerkinElmer, Waltham, MA, USA) using Phe-
nomenex Sphereclone 5 micro ODS(2) 250 mm× 4.6 mm
column and 75% methanol as a moving phase. The Flexar
HPLC system (PerkinElmer, Waltham, MA, USA) was
equipped with a Solvent Manager 5-CH degasser, an auto-
sampler, a quaternary LC pump, a column oven, and a
UV-visible detector. The flow rate was set to 1.5 ml/min
and the temperature at 50°C. The UV detector (226 nm)
was used for the measurement. To prepare the sample for
the measurement of HPLC, paclitaxel was dissolved in
ethanol, making 20 μl for injection.Antitumor activity of paclitaxel-incorporated
nanoparticles in vitro
Antitumor activity of paclitaxel-incorporated nanoparti-
cles was evaluated using HuCC-T1 human cholangiocar-
cinoma cells. HCT116 cells were seeded at a density of
2 × 103 cells per well in 96-well plates with 100 μl of
RPMI1640 supplemented with 10% FBS and incubated
overnight at 37°C and 5% CO2 atmosphere. After that,
free paclitaxel, paclitaxel-incorporated nanoparticles and








Figure 2 (See legend on next page.)
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Figure 2 TEM photos (A), typical size distribution (B), and 1H-NMR spectra of nanoparticles (C). (A) TEM photos of nanoparticles of PHO/PEG
block copolymer. PHO (a), PHO/PEG 2 K (b), PHO/PEG 5 K (c), and PHO/PEG 12 K (d). (B) Typical particle size distribution (e) of PHO/PEG 12 K nanoparticles.
(C) 1H-NMR spectra of nanoparticles of PHO/PEG block copolymer (PHO/PEG 12 K) in D2O (f) and CDCl3 (g).
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DMSO was diluted 1,000 times with RPMI1640 supple-
mented with 10% FBS and added to cells. For nanoparti-
cle treatment, paclitaxel-incorporated nanoparticles were
diluted with RPMI1640 supplemented with 10% FBS and
treated to cells. Controls were treated with 0.1% v/v of
dimethyl sulfoxide. For the testing of cellular cytotoxicity
of empty nanoparticles, they were diluted with serum-
free RPMI1640 media and sterilized with a 0.8-μm syr-
inge filter and added to 2 × 104 HCT116 cells. Viable
cells were evaluated with MTT cell proliferation assay as
described previously [9]. After 3 days of incubation,
30 μl of MTT (5 mg/ml) was added to the 96-well plates
and incubated for 4 h. The formazan crystals formed
were solubilized with SDS solution (100 μl of SDS-HCl
solution (SDS 10%w/v, 0.01 M HCl)) and the absorb-
ance (560-nm test/630-nm reference) was determined
using an automated computer-linked microplate reader
(Infinite M200 Pro microplate reader, Molecular Device
Company, Sunnyvale, CA, USA). Each measurement of
drug concentration was obtained as the mean value of
eight wells. The amount of formazan present is propor-
tional to the number of viable cells, because only living
cells will reduce MTT to blue formazan. The results were
expressed as a percentage of the absorbance present in the
drug-treated cells compared with that in the control cells.
Apoptosis/necrosis analysis
Apoptosis and necrosis of HCT116 cells were analyzed by
flow cytometry [9]. FITC-annexin V and PI were employed
to analyze apoptosis and necrosis of HCT116 cells,
respectively. Cells (1 × 106 cells) were exposed to pacli-
taxel or paclitaxel-incorporated nanoparticles in serum-
free RPMI1640 media for 48 h, and cells were washed
with phosphate-buffered saline (PBS). The cells were
harvested by trypsinization, and cell pellets were resus-
pended in a binding buffer (pH 7.4, 10 mM HEPES,
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM
CaCl2) containing FITC-annexin V (1 μg/ml) and thenTable 2 Characterization of paclitaxel-incorporated nanoparti
Polymer/drug (mg/mg) Drug c
Theoretical
PHO 45/5 10
PHO/PEG 2 K 45/5 10
PHO/PEG 5 K-1 45/5 10
PHO/PEG 5 K-2 40/10 20
PHO/PEG 12 K 45/5 10further incubated for 30 min. Ten minutes prior to ter-
mination of incubation, PI (10 μg/ml) were added to
stain necrotic cells under dark conditions. Following
that, the cells were immediately analyzed using a FACS-
can flow cytometer (Becton Dicknson Biosciences, San
Jose, CA, USA).
Antitumor activity of paclitaxel-incorporated nanoparti-
cles against animal tumor xenograft
The tumor xenograft model was employed to assess an-
titumor activity of paclitaxel or paclitaxel-incorporated
PA nanoparticles. HCT116 cells (5 × 106) were implanted
subcutaneously in the backs of mice (Athymic nude
BALB/c male mice, 20 g). When the diameter of tumor
mass was approximately 2 ~ 3 mm (10 days after), pacli-
taxel or paclitaxel-incorporated nanoparticles were injected
intravenously via tail vein of the mouse (paclitaxel dose =
10 mg/kg). The treatment group was divided as follows;
control - 200 μl of PBS (0.01 M, pH 7.4); paclitaxel treat-
ment - paclitaxel dissolved in Cremophor® EL/ethyl alcohol
(5:5, (v/v)) solution were mixed with aqueous solution of
empty nanoparticles; paclitaxel-nanoparticles prepared
from PHO/PEG 5 K - lyophilized nanoparticles were recon-
stituted in deionized water and sterilized with a 0.8-μm syr-
inge filter. Five mice were used for each treatment group.
At intervals of 5 days, length and width of solid tumor
was measured and tumor volume was calculated with the
following equation: Tumo volume (mm3) = Length ×
Width2. Tumor mass was taken from the back of mice
and the weight of tumor was compared between each of
the treatment groups 2.5 weeks after drug injection. All
animal experiments followed the guidelines of the Com-
mittee for the Care and Use of Laboratory Animals of
Pusan National University.
Statistical analysis
Results of animal experiments were expressed as aver-
age ± standard deviation, and statistical significance was
evaluated using the Student's t test (SigmaPlot programcles of PHO/PEG block copolymer







Figure 3 Drug release from paclitaxel-incorporated nanoparticles
of PHO/PEG block copolymers. The effect of PEG length (A) and drug
contents (B). NP, nanoparticles.
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p value <0.05 was considered significant.
Results
Characterization of PHO/PEG block copolymer
As reported previously, PHO was produced from P. oleo-
vorans ATCC 29347 using octanoate-supplemented min-
eral medium [8]. PHO was purified from lyophilized
cells by extraction with hot chloroform because cell ly-
sates were not soluble in chloroform and PHO can be
solved in it. The purified PHO was composed of 3-
hydroxyhexanoate (7%) and 3-hydroxyoctanoate (93%)
[8]. To synthesize block copolymers composed of PHO
and PEG, carboxylic end group of PHO was activated
using DCC and NHS, and then PHO-NHS was reacted
with various M.W. of MPEG-amine (Figure 1A). Since
MPEG-amine is soluble in methanol, reactants were pre-
cipitated into methanol. Final product was analyzed
using 1H-NMR spectroscopy in CDCl3. The chemical
structures of PHO/PEG block copolymer were shown in
Figure 1B,C. As shown in Figure 1B, typical 1H-NMR
spectra of the PHO homopolymer showed specific peaksaround 0.9, 1.3, 1.6, 2.56, and 5.2 ppm, respectively. In
the PHO/PEG block copolymer as shown in Figure 1C,
the ethylene peak of PEG appeared at 3.65 ppm. M.W.
of PHO homopolymer and PHO/PEG block copolymer
were analyzed using GPC as shown in Table 1. As shown
in Table 1, the M.W. of PHO/PEG block copolymer was
increased as much as PEG M.W. at each sample even
though the gap of M.W. was not exactly the same. These
results indicated that MPEG was successfully attached to
the carboxylic end of the PHO block.
Characterization of paclitaxel-incorporated nanoparticles
Nanoparticles of PHO/PEG block copolymers were fab-
ricated by nanoprecipitation-diafiltration method, i.e.
block copolymer dissolved in solvent was precipitated
into deionized water to make nanoparticles and solvent
was removed by dialysis membrane. To confirm whether
or not nanoparticles were formed, nanoparticle solution
was analyzed using dynamic light scattering and TEM.
As shown in Figure 2A, nanoparticles were successfully
fabricated at all of the polymers and their average par-
ticle sizes were less than 100 nm (Figure 2B). Further-
more, particle sizes were decreased according to the
increase of M.W. PEG block (Table 1), indicating that
hydrophilic nature of PEG block might have increased
hydrophilicity of block copolymer by higher M.W. of
PEG since PEG is a water-soluble polymer. The higher
M.W. of PEG in the block copolymer is known to cause
decreased particle size, increased colloidal stability, and
increased biological properties [10]. Since block copoly-
mers composed of hydrophilic and hydrophobic blocks
are normally formed nanoparticles with core-shell struc-
ture, nanoparticles of PHO/PEG block copolymer were
examined using 1H-NMR spectroscopy with D2O. As
shown in Figure 2C, specific peaks of PEG were only
observed when nanoparticles were distributed in D2O
(Figure 2C(f )). When nanoparticles were added to
CDCl3, however, specific peaks both PHO and PEG
appeared as shown in Figure 2C(g). These results indi-
cated that nanoparticles of PHO/PEG block copolymers
are formed core-shell structures, i.e., PEG block con-
sisted an outer shell of nanoparticles while PHO block
consisted a solid inner core of nanoparticles.
Paclitaxel was loaded into nanoparticles by nanopreci-
pitation and dialysis procedure. Even though direct dia-
lysis was also possible to form nanoparticles, it also
induced the increase in particle size higher than 300 nm
(data not shown) while nanoprecipitation resulted in
reduced particle size. Because DMF is a non-volatile
solvent and hard to remove by evaporation, the
remaining solvent was removed by dialysis. The results
of paclitaxel-incorporated nanoparticles of PHO/PEG
block copolymers are summarized in Table 2. As shown
in Table 2, the higher M.W. of PEG induced the
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ciency as well. Furthermore, drug entrapment into
nanoparticles induced the increase in particle size com-
pared that into empty nanoparticles. The higher the
drug feeding ratio, the higher the drug contents and
average size of nanoparticles.
Figure 3 shows paclitaxel release from the nano-
particles of PHO/PEG block copolymer. As shown in
Figure 3A, the higher M.W. of PEG block induced
increase of faster drug release rate than the lower M.
W. of PEG block. The higher PEG M.W. is known to
accelerate drug release rate [10]. Initial burst release
of drug was observed until 12 h and then drug
release profile was relatively continuous manner. Fur-
thermore, increased drug contents induced slower re-
lease rate of drug as shown in Figure 3B. Since
paclitaxel is hydrophobic drug, hydrophobic interac-
tions might be increased at higher drug content and
this phenomenon caused decreased drug release rate.
At higher drug contents, hydrophobic drug can be ag-
gregated in the solid core of the nanoparticles and
aggregated drug release slowly from the nanoparticles
[2,3]. Furthermore, larger particle size at higher
drug loading might be the one of reason for slower
release [11].Figure 4 Growth inhibition and cell cytotoxicity (A) and cell morpholog
incorporated PHO/PEG 5 K nanoparticles (NP) against HCT116 cells (a). Surviva
treated to tumor cells for 2 days (b). (B) Cell morphology with treatment of p
For 0 μg/ml of nanoparticle treatment, 10 μg/ml of empty nanoparticles were
Empty NP, empty nanoparticles.Antitumor activity of paclitaxel-incorporated
nanoparticles
The antitumor activity of paclitaxel-incorporated nano-
particles of PHO-PEG block copolymer was tested using
HCT116 human colon carcinoma cells in vitro. As
shown in Figure 4A(a), viable cells were decreased ac-
cording to the exposure time of paclitaxel. Especially,
paclitaxel-incorporated nanoparticles showed enhanced
antiproliferation activity at the same paclitaxel dose while
empty nanoparticles did not show anti-proliferation effect
against tumor cells as shown in Figure 4A(b). Figure 4B
showed cell morphology according to the treatment of pac-
litaxel or paclitaxel nanoparticles. As shown in Figure 4B,
cell density was decreased according to the increase of pac-
litaxel dose. Cells were crowded at a lower dose of pacli-
taxel while they were scattered at a higher concentration of
paclitaxel.
Figure 5 shows the apoptosis/necrosis analysis of HCT116
cells with treatment of paclitaxel and paclitaxel nanoparti-
cles. As shown in Figure 5, apoptotic cells were dose-de-
pendently increased and, especially, apoptotic cells with
treatment of paclitaxel nanoparticles were practically simi-
lar to those treated with paclitaxel even though they were
slightly higher. These results also supported those of
Figure 4.y (B) of nanoparticles. (A) Growth inhibition of paclitaxel or paclitaxel-
bility of HCT116 was measured by MTT assay. Empty nanoparticles were
aclitaxel, empty nanoparticles, and paclitaxel-incorporated nanoparticles.
treated to cells. Paclitaxel NP, paclitaxel-incorporated nanoparticles.
Figure 5 Flow cytometric analysis of HCT116 cells. Annexin V was used for apoptosis analysis and PI was used for necrosis analysis. HCT116
cells with treatment of paclitaxel, empty nanoparticles, and paclitaxel-incorporated nanoparticles (PHO/PEG 5 K).
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nanoparticles against HCT116 cells were evaluated with
tumor xenograft model using nude mice. As shown in
Figure 6, tumor weight with treatment of paclitaxel
nanoparticles were significantly lower than that of control
or paclitaxel + empty nanoparticles while paclitaxel +
empty nanoparticles were not significantly changed tumor
mass compared to control. At least, tumor mass of mice
treated with paclitaxel nanoparticles were three times
smaller than that of paclitaxel + empty nanoparticles. The
antitumor activity of paclitaxel at the animal tumor xeno-
graft model might be due to the sustained release functionof nanoparticles. These results indicate that paclitaxel-
incorporated nanoparticles are a potent anticancer agent
compared to conventional carriers.
Discussion
Nanoparticles are regarded as ideal vehicles for antican-
cer drug targeting due to their intrinsic physicochemical
properties [12]. Even though various active targeting using
receptor-ligand interaction strategy have been investigated
successively [12-15], passive targeting using plain nano-
particles or PEGylated nanoparticles are still preferentially
considered for tumor targeting due to the vasculature
Figure 6 Tumor mass of HCT116 tumor xenograft-induced
nude mice. Ten days after tumor implantation, drug solution was
injected intravenously (Paclitaxel dose 10 mg/kg). Control - PBS (0.1 M,
pH 7.4); Paclitaxel + Empty nanoparticle treatment - paclitaxel
dissolved in Cremophor EL/ethanol mixture (5/5, v/v) was diluted
ten times with PBS and mixed with aqueous solution of empty
nanoparticles (the content of empty nanoparticles in this treatment
were adjusted to similar concentration with paclitaxel NP
treatment; paclitaxel-incorporated nanoparticles (Paclitaxel
NP) - aqueous solution of paclitaxel-incorporated nanoparticles
(PHO/PEG 5 K) was sterilized with a 0.8-μm syringe filter.
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numerous biological and physiological elimination mecha-
nisms of tumor preferentially decide the fate of nano-
vehicles prior to their access in the tumor cells [16]. Until
the nanocarriers are close to the cell surfaces, no specific
interaction between receptor on the tumor cell surface and
ligand on the nanoparticle surface happens. At this mo-
ment, the preferential translocation of nanoparticles from
blood circulation to tumor vasculature (so-called enhanced
permeation and retention (EPR) effect) is still considered
for a solid tumor targeting [16,17]. Diameter of nano-
particles less than 200 nm are known to have advantages
for drug targeting because this size could increase blood
circulation by avoiding reticuloendothelial system (RES)
and then increase chance to access the microvessel of the
tumor tissue [17,18].
In this study, we synthesized PHO/PEG block copoly-
mers and prepared paclitaxel-incorporated core-shell-
typed nanoparticles for anticancer drug delivery. There
are very few reports on the drug delivery application
with PHO in spite of their defined structure and good
biocompatibility [6,19-21]. The main drawback of PHO
is slow degradation in vitro and in vivo [6,19]. In a pre-
vious research, graft-copolymerization with PEG acceler-
ated hydrolytic degradation of polymers [6]. PHO/PEG
block copolymer was synthesized by the attachment of
PEG to the carboxylic end of PHO. We prepared PHO/
PEG block copolymers by varying M.W. of PEGs and its
effect on the physicochemical properties of nanoparticleformation. We found that higher M.W. of PEG decreased
particle size of nanoparticles even though it slightly
decreased drug loading contents (in Tables 1 and 2).
For antitumor drug delivery, paclitaxel was selected
as an anticancer drug because it is commonly used in
the clinics and has strong hydrophobic property (aque-
ous solubility is less than 0.3 μg/ml) and it has a
specific interaction with serum proteins [22]. Due to
its poor aqueous solubility, specific surfactant/solvent
mixtures (Cremophor EL/ethanol mixture) are com-
mercially used. However, due to the intrinsic toxicity
of specific surfactant, various formulations for enhancing
aqueous solubility of paclitaxel have been investigated such
as nanoparticles, liposomes, and polymeric micelles
[23]. Since PEG has a protective effect for the adsorp-
tion of protein and macrophage cells, PEGylation of
nanocarriers may enhance blood circulation time of
nanocarriers, unwanted content with serum protein/
macrophage cells, and then chance to contact tumor
tissues in vivo.
Paclitaxel was incorporated into the nanoparticles by
nanoprecipitation and dialysis procedure. The size of
paclitaxel nanoparticles was slightly increased compared
to that of empty nanoparticles. Even though the diam-
eter of nanoparticles was increased with paclitaxel load-
ing, the average size of nanoparticles did not exceed
200 nm. Furthermore, paclitaxel was slowly released
from the nanoparticles for over 6 days. In a drug release
study, diffusion from nanoparticles must be the preferential
mechanism rather than the degradation of polymer be-
cause PHO itself has very slow degradation kinetics [6,19].
Nanoparticles showed practically similar anticancer activity
against tumor cells as shown in Figure 4. Furthermore,
nanoparticles showed practically similar effect on the ap-
optosis and necrosis of tumor cells as shown in Figure 5.
Antitumor activity of paclitaxel nanoparticles in vivo was
evaluated using HCT116 tumor-bearing mice as shown in
Figure 6. As shown in Figure 6, paclitaxel nanoparticles sig-
nificantly inhibited growth of tumor mass compared to the
control and the paclitaxel plus empty nanoparticles. Even
though nanoparticles have no practical advantages in anti-
cancer activity in vitro, they properly suppressed growth of
tumor mass in vivo the tumor xenograft model as shown
in Figure 6 while paclitaxel itself seemed to have minimal
anticancer activity. The EPR effect of the nanoparticles
can be considered to explain these results, i.e., nano-
particles properly entered into the cells and killed the
tumor cells [16,17]. Otherwise, paclitaxel itself could be
absorbed to the serum protein in the blood and rapidly
cleared from blood circulation. Then, these factors can
induce decrease in opportunities for tumor targeting
[22]. Therefore, paclitaxel nanoparticles formed by
PHO/PEG block copolymer are a promising vehicle for
antitumor drug delivery.
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Paclitaxel-incorporated nanoparticles were prepared
using PHO/PEG block copolymers for antitumor drug
delivery. Paclitaxel-incorporated nanoparticles of PHO/
PEG block copolymer have spherical morphology with
small particle size less than 100 nm. In a 1H-NMR
study in D2O, the core-shell structure of PHO/PEG
nanoparticles was confirmed. The higher M.W. of PEG
decreased loading efficiency of drug and particle size.
The higher drug feeding resulted in increased drug
contents and average size of nanoparticles. The higher
M.W. of PEG block accelerated drug release rate while
higher drug contents delayed the release rate of drug. In
an antitumor activity study using HuCCT1 cells in vitro,
paclitaxel-incorporated nanoparticles have similar antipro-
liferation activity against HCT116 tumor cells. However,
paclitaxel nanoparticles showed enhanced antitumor activ-
ity against HCT116 tumor cells of mice in vivo.
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